Abstract
Objective: Current evidence suggests that statin use decreases the incidence of cardiovascular diseases (CVD) through reducing LDL cholesterol and decreasing inflammation. Metabolic syndrome (MetS) is usually associated with increased inflammatory markers and increased risk of CVD. We conducted a systematic review and meta-analysis to determine the effect of statin use on inflammatory markers including C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 (IL-1) among patients with MetS and related disorders. Methods: PubMed, EMBASE, Web of Science databases, and Cochrane Library were searched for randomized controlled trials (RCTs) through April 2018. Three independent investigators evaluated study eligibilities, extracted data, and assessed study quality using the Cochrane Collaboration risk of bias tool and Jadad's quality scales. Heterogeneity was determined using Cochran's Q statistic and I-square (I2) test. Based on the heterogeneity results, we pooled data using random-effect or fixed effect models presented as standardized mean differences (SMD) and corresponding 95% confidence intervals (CI). Results: One hundred thirteen RCTs (19,644 patients) were included in our meta-analysis. The pooled results using random effects model showed that statin use statistically significantly decreased CRP level (SMD= -0.97; 95% CI, -1.10, -0.85; P<0.001; I2: 95.1 %), TNF-α (SMD= -1.88; 95% CI, - 2.40, -1.38; P<0.001; I2: 97.2 %), IL-6 (SMD= -1.70; 95% CI, -2.03, - 1.40; P<0.001; I2: 96.5 %), and IL-1 concentrations (SMD= -8.35; 95% CI, -10.49, -6.22; P<0.001; I2: 98.4 %) among patients with MetS and related disorders. Conclusion: Our meta-analysis showed beneficial effects of statin use on reducing inflammatory markers in patients with MetS and related disorders. Funding Statement: The research grant provided by Research Deputy of Shiraz University of Medical Sciences (SUMS) with grant number 97-01-106-17583. Declaration of Interests: The authors declare no conflict of interest.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
